Summary: In this article, Catalent expert George Buchman discusses the recent increase in gene therapy approvals & how we can accelerate the manufacturing speed with platform processes.

A poster presentation of how Catalent's GPEx® Lightning system enables faster development timelines, robust manufacturing processes, improved titers, and higher final yields.

In this episode of “The Top Line”, Fierce Pharma’s Fraiser Kansteiner interviews Delara Motlagh, head of cell therapy at Catalent; Becky Butler Cap, senior vice president of biotherapies at Vitalant; and Kevin Kyle, CEO of Germfree. The conversation covers cell collection, the critical first step in advanced therapy manufacturing.

Summary: Learn about the major achievements in the gene therapy market in 2023, with a focus on reliable manufacturing processes and strategies to enhance predictability while reducing waste in gene therapy manufacturing.

Summary: Learn about the major achievements in the gene therapy market in 2023, with a focus on reliable manufacturing processes and strategies to enhance predictability while reducing waste in gene therapy manufacturing.

This webinar explored the challenges of cell therapy manufacturing and introduced Catalent's UpTempo CAR-T Platform process as a solution.

Summary: In a recent presentation during the 2024 JP Morgan Healthcare Conference, Catalent’s Group President of Biologics Dave McErlane addresses the latest market drivers for Biologics and Sterile Injectables.

Learn about pluripotent stem cells and how they're being explored as an exciting alternative gene therapy technology with the potential to transform the field of regenerative medicine.

In recent years, the field of gene therapy has witnessed remarkable achievements and advancements. These breakthroughs have brought us even closer to unleashing the full potential of gene therapies. Catalent gene therapy experts discuss all aspects of gene therapy commercialization in depth.

A poster presentation of a GMP manufacturing process for the creation of human iPSC for use in allogeneic cell therapy applications.